Full Title
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid TumorsPurpose
Researchers want to find the best dose of a new cell therapy called AFNT-211 for people with solid tumors. The people in this study have solid tumors that have metastasized (spread) and keep growing even after treatment. In addition, their tumors have a mutation (change) in a gene called KRAS G12V. They also have HLA-A*11:01, a protein that your immune system can use to help recognize cancer cells.
AFNT-211 is made from your own white blood cells called T cells. Some types of cancer can block T cells from attacking cancer cells. If you join this study, we will collect some of your T cells and modify (change) them in a lab. The modified T cells are then returned to your body to detect and destroy cancer cells.
Before you get AFNT-211, you will get fludarabine and cyclophosphamide. These chemotherapy drugs will prepare your body to receive AFNT-211. These treatments are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic solid tumor that keeps growing even after treatment and has a KRAS G12V mutation.
- Have HLA-A*11:01.
- Have recovered from the serious side effects of prior therapies before getting the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Adam Schoenfeld at 646-608-2091.